RNS Number : 1835G
ValiRx PLC
04 November 2025

4 November 2025

ValiRx PLC

("ValiRx" or the "Company")

Posting of Circular and Notice of General Meeting

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement made on 30 October 2025, a circular (the "Circular"), including the Notice of General Meeting and a Form of Proxy, has been posted to shareholders.

The General Meeting will be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT at 11 a.m. on 20 November 2025.

A copy of the Circular will shortly be available on the Company's website at https://www.valirx.com/aim-rule-26.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 30 October 2025.

FUNDRAISING STATISTICS

Issue Price	0.25 pence
Number of Existing Shares	374,348,672
Number of Tranche 1 Placing Shares	112,304,600
Number of Tranche 2 Placing Shares	183,695,400
Aggregate Number of Placing Shares	296,000,000
Number of WRAP Retail Offer Shares	60,722,400
Number of Subscription Shares	4,000,000
Number of Fee Shares	7,650,000
Aggregate Number of New Ordinary Shares to be issued in connection with the Fundraising	368,372,400
Number of Shares in issue following Admission and issue of the New Ordinary Shares	742,721,072
Percentage of the Enlarged Share Capital represented by the New Ordinary Shares	49.60%
Number of Fundraising Warrants to be issued following Admission	368,372,400
Number of Broker Warrants to be issued following Admission	16,036,120
Gross proceeds of the Placing	£740,000
Gross proceeds of the WRAP Retail Offer	£152,000

Gross proceeds of the Subscription	£10,000
Gross proceeds of the Fundraising	£902,000
Ordinary Share ISIN	GB00BLH13C52

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

	2025
Announcement of the Fundraising	30 October
Launch of the WRAP Retail Offer	30 October
Date of publication and posting of this Circular & the Form of Proxy	4 November
Announcement of the results of the WRAP Retail Offer	4 November
Admission and dealings in the Tranche 1 Placing Shares expected to commence on AIM	8:00 a.m. on or around 6 November
Expected date for CREST accounts to be credited for Tranche 1 Placing Shares to be held in uncertificated form	6 November
Despatch of definitive share certificates in respect of the Tranche 1 Placing Shares to be held in certificated form, if applicable	by 20 November
Latest time and date for receipt of CREST Proxy Votes or the completed Forms of Proxy	11.00 a.m. on 18 November
General Meeting	11.00 a.m. on 20 November
Announcement of the results of the General Meeting	20 November
Admission and dealings in the Tranche 2 Placing Shares, Subscription Shares, Fee Shares and WRAP Retail Offer Shares expected to commence on AIM	8:00 a.m. on or around 21 November
Expected date for CREST accounts to be credited for Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares, Fee Shares and Fundraising Warrants to be held in uncertificated form	21 November
Despatch of definitive share certificates in respect of the Tranche 2 Placing Shares, Subscription Shares, WRAP Retail Offer Shares, Fee Shares and Fundraising Warrants to be held in certificated form, if applicable	by 5 December

Notes:

1. Each of the times and dates above are indicative only and if any of the details contained in the timetable above should change, the revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service.

2. All of the above times refer to London time unless otherwise stated.

3. All events listed in the above timetable related to the granting of the Fundraising Warrants and the Broker Warrants and Admission of the Tranche 2 Placing Shares, the Subscription Shares, the WRAP Retail Offer Shares and the Fee Shares are conditional on the passing at the General Meeting of the Fundraising Resolutions to provide the relevant authorities.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/yVwkje
ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 115 784 0026** www.valirx.com Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Shard Capital Partners LLP (Broker) Damon Heath Andrew Gutmann	**Tel: +44 (0) 20 7186 9000**
SP Angel Corporate Finance LLP (Placing Agent) David Hignell Vadim Alexandre	**Tel: +44 (0) 20 3470 0470**
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz

Background to and Reasons for the Fundraising

ValiRx is an AIM-quoted life science company focused on cancer therapeutics and women's health. The Company seeks to identify the most promising research in academia and innovative biotechnology companies and translate this research towards clinical development, providing a pathway to commercialisation.

The Company has identified certain fundamental issues impacting drug development today, in terms of innovation, productivity and access. A lack of expertise in early-stage drug developers, particularly in academia, contributes to low rates of success in translating novel scientific research into valuable new therapeutic assets, hindering both the adoption of innovation and the overall productivity of developing new treatments.

To address these fundamental issues, ValiRx has adopted a strategy to improve the efficacy of translating promising novel research into the preclinical development phase, with a particular focus on women's health and oncology. Combining its clinical knowledge, deep biological expertise, data generation and data interpretation abilities, ValiRx seeks to unlock the substantial potential of early-stage innovation and provide a specialist service for its in-house collaborative projects and third-party innovators through its subsidiary, Inaphaea Biolabs Limited ("**Inaphaea**").

Use of Proceeds

The proceeds of the Fundraising, in aggregate of approximately £902,000 (before expenses), are intended to be used by the Group for the following:

	Estimated cost
· R&D: invest into the ValiRx future collaborative pipeline	£0.4m
· R&D: preclinical development of Cytolytix	£0.2m
· R&D: preclinical development of VAL201 2.0	£0.05m
· Operating costs (balance from R&D tax credits, revenue and grants)	£0.25m

For the purposes of section 571(6)(c) of the Companies Act 2006, the Issue Price has been determined by the Company following discussions with market participants and its professional advisers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGEAXFLEFDSFFA